Spironolactone
Product Images NDC 17856-2028

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Spironolactone (NDC 17856-2028). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Atlantic Biologicals Corp., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image Description (17856 2028 02)

This text provides information about the medication Carospir (spironolactone) in oral suspension form. Each 5 mL of the suspension contains 25mg of spironolactone, delivering 12.5mg per 2.5mL. It is indicated for specific purposes and has a specified dosage schedule, as detailed in the package insert. The medication should be stored at a temperature range of 20°-25°C (68°-77°F) with excursions permitted between 15°-30°C (59°-86°F). The text also mentions the importance of keeping all medications out of the reach of children. The packaging includes a batch number, expiry date, and the manufacturer's details.*

FDA Label Image

Image Description (17856 2028 03)

This text is a detailed description of Carospir oral suspension, containing Spironolactone at a strength of 25mg per 5mL, delivering 12.5mg per 2.5mL. It provides instructions to refer to the package insert for indications and dosage schedule, emphasizes oral use only, and storage recommendations between 20°-25°C (68°-77°F) with excursions permitted between 15°-30°C (59°-86°F). The text also mentions keeping the medication out of the reach of children and includes details about the product such as the dosage, quantity, GTIN, expiration date, lot number, and packaging information. Additionally, there is contact information for reordering.*

FDA Label Image

Structural Formula (Spironolactone Oral Suspension 1)

FDA Label Image

Figure 1 (Spironolactone Oral Suspension 2)

This is a graph showing the survival rates by treatment group in a study called RALES. The study compared the effectiveness of Spirorolactone and Placebo treatments on 822 and 841 subjects, respectively. The log-rank p-value is less than 0.001, indicating a significant difference between the two groups in terms of survival rates over the span of 42 months.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.